Evidence map›Paper›PMID 30359624›Full record

ArticleJournal of the American Academy of Dermatology2019

The prognostic value of inositol polyphosphate 5-phosphatase in cutaneous squamous cell carcinoma.

Helen J L Cumsky, Collin M Costello, Nan Zhang, Richard Butterfield, Matthew R Buras, Jessica E Schmidt, Kevin Drenner, Steven A Nelson, Shari A Ochoa, Christian L Baum and 4 more

Open access · greenAbstract read
In one paragraph

Article in Journal of the American Academy of Dermatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Helen J L CumskyDepartment of Dermatology, Mayo Clinic, Scottsdale, Arizona; Case Western Reserve University School of Medicine, Cleveland, Ohio.
Collin M CostelloDepartment of Dermatology, Mayo Clinic, Scottsdale, Arizona.
Nan ZhangDepartment of Health Science Research, Mayo Clinic, Scottsdale, Arizona.
Richard ButterfieldDepartment of Health Science Research, Mayo Clinic, Scottsdale, Arizona.
Matthew R BurasDepartment of Health Science Research, Mayo Clinic, Scottsdale, Arizona.
Jessica E SchmidtDepartment of Dermatology, Mayo Clinic, Scottsdale, Arizona.
Kevin DrennerDepartment of Dermatology, Mayo Clinic, Scottsdale, Arizona.
Steven A NelsonDepartment of Dermatology, Mayo Clinic, Scottsdale, Arizona.
Shari A OchoaDepartment of Dermatology, Mayo Clinic, Scottsdale, Arizona.
Christian L BaumDepartment of Dermatology, Mayo Clinic, Rochester, Minnesota.
Mark R PittelkowDepartment of Dermatology, Mayo Clinic, Scottsdale, Arizona.
David J DiCaudoDepartment of Dermatology, Mayo Clinic, Scottsdale, Arizona.
Aleksandar SekulicDepartment of Dermatology, Mayo Clinic, Scottsdale, Arizona.
Aaron R MangoldDepartment of Dermatology, Mayo Clinic, Scottsdale, Arizona. Electronic address: Mangold.aaron@mayo.edu.
Mayo Clinic in Arizona · USMayo Clinic · US

Funding

Novel Therapeutics Targeting INPP5A Pathway in Squamous Cell CarcinomaR01CA179157 · NCI · MAYO CLINIC ARIZONA · PI SEKULIC, ALEKSANDAR NONE · 2014 to 2018
$1.8M
NCI NIH HHS R01 CA179157
6 · The paper itself

Abstract

backgroundInositol polyphosphate 5-phosphatase (INPP5A) has been shown to play a role in development and progression of cutaneous squamous cell carcinoma (cSCC). The goal of the current study was to explore the prognostic value of INPP5A expression in cSCC.

methodsA total of 189 cases of actinic keratosis and SCC in 174 patients were identified; clinical and outcome data were abstracted, histopathology was rereviewed, and immunohistochemical staining and interpretation was performed for INPP5A.

resultsThe majority of tumors (89.4%) had an INPP5A score of 2 or 3. No patients had complete loss of INPP5A. Tumors with an INPP5A score of 1 were more likely to be intermediate- to high-risk tumors (Brigham and Women's Hospital stage ≥T2a 85.0% vs 23.7% [P < .0001]) characterized by a larger diameter (2.4 cm vs 1.3 cm [P = .0004]), moderate-to-poor differentiation (86.7% vs 17.6% [P < .0001]), and perineural invasion (37.5% vs 5.3%, [P < .0001]). An INPP5A score of 1 was associated with a worse 3-year survival (a rate of 42.3% [hazard ratio, 2.81, P = .0006]) and a local metastasis rate of 48.0% (hazard ratio, 4.71; P < .0001).

conclusionsLow INPP5A scores are predictive of aggressive tumors and may be a useful adjunct to guide clinical management of cSCC.

Indexed as

AgedAged, 80 and overBiomarkers, TumorCarcinoma, Squamous CellFemaleHumansInositol Polyphosphate 5-PhosphatasesKeratosis, ActinicMaleMiddle AgedNeoplasm GradingNeoplasm InvasivenessNeoplasm MetastasisPeripheral NervesPrognosisRetrospective StudiesBiomarkers, TumorInositol Polyphosphate 5-PhosphatasesINPP5A protein, humanbiomarkercancer tumor markercutaneous squamous cell carcinomainositol polyphosphate-5-phosphatasemetastasesoutcomeprognosisprognostic markerrecurrencesquamous cell carcinomastaging

Identifiers

PMID30359624
PMCPMC10577667
OpenAlexW2896456774

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.